The "Alagille Syndrome (ALGS) - Market Insights, Epidemiology, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Alagille Syndrome (ALGS), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Alagille Syndrome (ALGS) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Alagille Syndrome (ALGS) symptoms market size from 2017 to 2030 segmented by seven major markets. The report also covers current Alagille Syndrome (ALGS) symptoms treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities. It assesses the underlying potential of the market.
Alagille syndrome, also known as Alagille-Watson syndrome is a genetic disorder. It is an autosomal dominant disorder that is caused by a mutation in either the JAG1 or NOTCH2 gene. These genes are located on chromosomes 20 and 1, respectively, with more than 90% of the individuals having a mutation in JAG1. Although it is inherited in an autosomal dominant fashion in about half of cases, the mutation occurs as a new change ("de novo") in the individual and is not inherited from a parent. This disease is characterized by syndromic bile duct paucity and arteriohepatic dysplasia. This disease is characterized as a rare disease with an incidence of 1 in 30,000 children; it is equally prevalent in both genders.
However, several unmet needs of patients need to be addressed. It is essential that to provide holistic care to patients, novel diagnostic tools, and therapies that address the underlying cause of the disease need to be developed. Several challenges do exist like the rarity of the disease and poor research in the field.
Alagille Syndrome (ALGS) Diagnosis and Treatment
It covers the details of conventional and current medical therapies and diagnosis available in the Alagille Syndrome (ALGS) market for the treatment of the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The Alagille Syndrome (ALGS) market report gives a thorough understanding of Alagille Syndrome (ALGS) symptoms by including details such as disease definition, symptoms, causes, physiology, and diagnosis. It also provides Alagille Syndrome (ALGS) symptoms of treatment algorithms and treatment guidelines for Alagille Syndrome (ALGS) symptoms in the US, Europe, and Japan.
A diagnosis of ALGS is made based upon identification of characteristic symptoms, a detailed patient history, a thorough clinical evaluation and a variety of specialized tests as the symptoms are highly variable and obtaining a diagnosis can be difficult. Surgical removal and microscopic study of liver tissue (liver biopsy) can reveal bile duct paucity. Although bile duct paucity is considered a key characteristic of Alagille syndrome, this finding is not always present in infants with the disorder.
The treatment of Alagille syndrome is directed toward the specific symptoms that are apparent in each individual. Treatment may require the coordinated efforts of a team of specialists. Pediatricians, gastroenterologists, cardiologists, ophthalmologists, and other healthcare professionals may need to systematically and comprehensively plan an effective child's treatment.
Alagille Syndrome (ALGS) Epidemiology
The Alagille Syndrome (ALGS) symptoms epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Scope of the Report
The report covers the descriptive overview of Alagille Syndrome (ALGS), explaining its causes, signs and symptoms, physiology and currently available therapies
Comprehensive insight has been provided into the Alagille Syndrome (ALGS) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Alagille Syndrome (ALGS) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
A detailed review of Alagille Syndrome (ALGS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Alagille Syndrome (ALGS) market
In the coming years, Alagille Syndrome (ALGS) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
The companies and academics are working to assess challenges and seek opportunities that could influence Alagille Syndrome (ALGS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
Major players are involved in developing therapies for Alagille Syndrome (ALGS). Launch of emerging therapies will significantly impact the Alagille Syndrome (ALGS) market
Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Alagille Syndrome (ALGS) Report Insights
Alagille Syndrome (ALGS) Pipeline Analysis
Alagille Syndrome (ALGS) Market Size and Trends
Impact of upcoming Therapies
Alagille Syndrome (ALGS) Report Key Strengths
11 Years Forecast
Alagille Syndrome (ALGS) Epidemiology Segmentation
Key Cross Competition
Highly Analyzed Market
Alagille Syndrome (ALGS) Report Assessment
Current Treatment Practices
Pipeline Product Profiles
Market Drivers and Barriers
For more information about this report visit https://www.researchandmarkets.com/r/ft3430
View source version on businesswire.com: https://www.businesswire.com/news/home/20200811005707/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900